• United States
  • Canada
  • Mexico
  • China
  • Middle East
  • Japan
  • Europe
  • Sales
  • Marketing
emphycorp logo
emphycorp logo
  • About Us
    • About Us
    • Management and Advisors
    • OUR MEDICAL STUDIES
  • Our Drug Pipeline
    • Our Drug Pipeline
    • PULMONARY FIBROSIS TREATMENT®
    • COVID-19 TREATMENT®
    • COVID-19 LONG HAULERS TREATMENT®
    • FLU TREATMENT®
    • UNMET NEEDS BREATHING TREATMENT®
    • NON-STEROIDAL COPD NASAL SPRAY®
    • 70% LOWER STEROID COPD®
    • NON-STEROIDAL ALZHEIMER’S NASAL SPRAY®
    • CONCUSSIONS TREATMENT®
    • DRUG FREE CANCER PRE-TREATMENT®
    • SMOKING CESSATION ORAL SPRAY®
  • Conditions We Can Treat
    • HYPOXEMIA
    • PULMONARY FIBROSIS
    • COVID-19
    • COVID LONG HAULERS
    • FLU
    • ASTHMA
    • COPD
    • EMPHYSEMA
    • SARCOIDOSIS
    • CYSTIC FIBROSIS (CF)
    • CHRONIC BRONCHITIS
    • INTERSTITIAL LUNG DISEASE
    • VIRAL and BACTERIAL Infections
  • FDA Submissions
    • REGULATION OF NITRIC OXIDE
    • SODIUM PYRUVATE
    • N115 FDA SUBMISSIONS
  • Contact Us
    • Investor Relations
    • Partnerships
  • News/Press/Blog
    • Emphycorp News & Peer Reviewed Articles
    • PRESS RELEASES
    • Blog
    • NEW PULMONARY FIBROSIS TREATMENT
  • United States
  • Canada
  • Mexico
  • China
  • Middle East
  • Japan
  • Europe
  • Sales
  • Marketing

JAPANESE PRODUCTS

EmphyCorp’s Global N115 Technology has (7) U.S. Drug Patents and (3) Pending for all lung diseases.

Our technology is also globally patented in the USA, Canada, Mexico, Brazil, Japan, Australia, Europe, and China.

Japan
  1. Home
  2. Features
  3. Japan
emphycorp logo white

Terms and Conditions

Focus Pages

  • About Emphycorp
 
  • Emphycorp News
 
  • Investor Relations

Address

84 Park Avenue, Suite E-102
Flemington, New Jersey
08822 USA

Start a conversation

SALES: (973) 586-4421
MARKETING: (973) 586-4421

© 2025 Emphycorp Inc. . All rights reserved

Privacy Preference Center

Privacy Preferences